Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Axcan files Photofrin sNDA for Barrett’s esophagus

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Axcan supplemental NDA for Photofrin (porfimer photodynamic therapy) for treatment of high-grade dysplasia associated with Barrett's esophagus is granted orphan drug status. The filing is based on a 208-patient Phase III study showing ablation of dysplasia in 72% of patients using Photofrin plus oral omeprazole (AstraZeneca's Prilosec) vs. 31% for omeprazole alone (p<0.0001). A trend toward reduction of progression to esophageal cancer was also seen, with a 9.4% progression rate for Photofrin plus omeprazole vs. 18.6% for omeprazole. Photofrin is currently approved for use in esophageal, lung and bladder cancer

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts